Defiance Daily Target 2X Long MRNA ETF(MRNX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$119.07
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MRNX

11/20/2026: MRNX (1-star) is currently NOT-A-BUY. Pass it for now.

The Defiance Daily Target 2X Long MRNA ETF (MRNX) provides leveraged synthetic exposure designed to deliver twice the daily price return of Moderna, Inc. through swap agreements. Its main strengths lie in offering efficient short-term tactical leverage and single-stock access without requiring a margin account. The fund serves as an active trading tool for expressing bullish momentum views on Moderna over single-session horizons. Primary risks include severe volatility decay, compounding erosion over multi-day periods, and extreme single-stock concentration. It is tailored strictly for experienced short-term traders who closely monitor their positions and market conditions.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitLeveraged single-stock ETFs are designed for short-term tactical trading rather than long-term growth investing.
Momentum investorStrong fit while signal remains positiveActive momentum traders can utilize its 2x daily leverage to capitalize on short-term bullish breakouts in Moderna shares.
Value investorWeak fitThe fund's daily reset mechanism and derivative overlays make it entirely unsuitable for traditional fundamental value strategies.
Dividend/Income investorWeak fitMRNX does not focus on dividend income and is designed exclusively for capital appreciation via short-term leverage.
Low-risk investorWeak fitHigh volatility, compounding risk, and single-stock concentration make this product inappropriate for conservative capital preservation.

Investor Profile

Ideal Investor Profile

Active tactical traders, day traders, and sophisticated short-term speculators seeking leveraged bullish exposure to Moderna without margin accounts.

Suitability

Best suited exclusively for intraday or very short-term tactical holding periods; entirely unsuitable for buy-and-hold or long-term investors.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighMagnified daily movements and compounding effects can lead to rapid capital erosion during choppy market conditions.
Market riskHighThe fund's value is directly vulnerable to adverse price drops in Moderna shares.
ConcentrationHighThe portfolio has 100% synthetic concentration tied to a single underlying corporate security (Moderna).
Tracking/expenseMedium / highHigher expense ratios and compounding divergence over holding periods longer than one day impact net returns.
LiquidityMediumTrading volumes can fluctuate based on news cycles surrounding the underlying stock, impacting execution costs.
Business/sector qualityHighThe fund's viability depends entirely on the operational performance and clinical pipeline success of Moderna.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

MRNX exhibits high historical volatility driven by daily 2x leverage compounding and the inherent price swings of Moderna stock.

Market Risk

Carries extreme single-issuer risk, meaning negative news or sharp downward corrections in Moderna directly inflict magnified losses.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
Single stockModerna Inc. (MRNA) — seeks 2x daily return100Provides leveraged synthetic exposure aiming to double the daily price movements of Moderna, Inc. shares.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type ETF
Historic Profit 16.61%
Avg. Invested days 13
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
ETF Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.